Monitoring the immune system during breast cancer drug treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 85.
- Your breast cancer has been confirmed as invasive (infiltrating) by biopsy.
- Your cancer is either triple-negative, or hormone-receptor positive but HER2 negative.
- You are starting or currently receiving one of these types of treatment: paclitaxel, epirubicin plus cyclophosphamide, eribulin, or (for certain first-line metastatic cases) palbociclib/abemaciclib/ribociclib with hormone therapy.
- You can sign the informed consent and attend all study visits, blood tests, and follow-up as planned.
- You are able to understand and follow the study, and you are in your country’s health coverage/social security system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system changes in people with breast cancer, using patient tissue samples. It may help researchers understand immune responses in young women and guide future cancer treatments.
This study looks at how your immune system changes while you receive standard breast cancer treatment around the time of surgery. The goal is to learn why some people respond better than others, which could help future treatment choices.
This study looks at how certain immune cells behave in people with breast cancer. It may help researchers understand the disease and how the immune system affects it.
This study looks at how your immune system and cancer cells interact. It may help doctors understand your cancer better and could lead to new treatments.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.